Vical Incorporated (VICL) Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
11/4/2009 8:35:24 AM
More...
|
Vical Incorporated (VICL) Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results
10/28/2009 8:26:24 AM
More...
|
Vical Incorporated (VICL) to Present at BIOCOM Investor Conference
10/27/2009 8:44:46 AM
More...
|
Vical Incorporated (VICL)'s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi Pasteur (SASY.PA) Fluzone(R) Seasonal Influenza Vaccine
10/26/2009 8:43:21 AM
More...
|
Vical Incorporated (VICL)'s TransVax(TM) CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial
10/7/2009 8:50:47 AM
More...
|
U.S. Navy to Fund Vical Incorporated (VICL)'s H1N1 Pandemic Influenza (Swine Flu) Vaccine
10/1/2009 8:48:46 AM
More...
|
Vical Incorporated (VICL) Licensee Sanofi-Aventis (France) (SASY.PA) Completes Enrollment in Phase 3 Angiogenesis Trial
9/28/2009 8:38:38 AM
More...
|
Vical Incorporated (VICL) Presents Positive Preclinical Results with Vaxfectin(R)-Formulated, Peptide-based Cancer Vaccine
9/24/2009 9:55:46 AM
More...
|
Detailed Data From Vical Incorporated (VICL)'s TransVax(TM) CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC
9/14/2009 9:18:52 AM
More...
|
Vical Incorporated (VICL) (JOBS) Says H1N1 Vaccine Showed Promise in Animals
9/10/2009 6:51:34 AM
More...
|
|